David O. Clarke

684 total citations
19 papers, 455 citations indexed

About

David O. Clarke is a scholar working on Molecular Biology, Small Animals and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, David O. Clarke has authored 19 papers receiving a total of 455 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 4 papers in Small Animals and 4 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in David O. Clarke's work include Animal testing and alternatives (4 papers), Effects and risks of endocrine disrupting chemicals (3 papers) and Carcinogens and Genotoxicity Assessment (3 papers). David O. Clarke is often cited by papers focused on Animal testing and alternatives (4 papers), Effects and risks of endocrine disrupting chemicals (3 papers) and Carcinogens and Genotoxicity Assessment (3 papers). David O. Clarke collaborates with scholars based in United States, United Kingdom and Switzerland. David O. Clarke's co-authors include Timothy R. Fennell, Robert O. Beauchamp, Frank Welsch, Kevin T. Morgan, Nigel A. Brown, Rory B. Conolly, Barbara A. Elswick, Charles A. Mebus, Afshan McCarthy and Frederick J. Miller and has published in prestigious journals such as Psychopharmacology, Clinical Pharmacology & Therapeutics and Toxicology and Applied Pharmacology.

In The Last Decade

David O. Clarke

18 papers receiving 427 citations

Peers

Countries citing papers authored by David O. Clarke

Since Specialization

Citations

This map shows the geographic impact of David O. Clarke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David O. Clarke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David O. Clarke more than expected).

Fields of papers citing papers by David O. Clarke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David O. Clarke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David O. Clarke. The network helps show where David O. Clarke may publish in the future.

Co-authorship network of co-authors of David O. Clarke

This figure shows the co-authorship network connecting the top 25 collaborators of David O. Clarke. A scholar is included among the top collaborators of David O. Clarke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David O. Clarke. David O. Clarke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Opportunities and challenges for use of minipigs in nonclinical pharmaceutical development: Results of a follow-up IQ DruSafe survey 2024 ·Regulatory Toxicology and Pharmacology ·David O. Clarke, (unknown), Kevin J. French, Michael W. Leach, (unknown), Susanne Mohr, (unknown), Jeanine L. Bussiere, Bianca Feyen, (unknown), Michael J. Graziano, (unknown), (unknown), (unknown), (unknown), R. D. Lange, (unknown), (unknown), Naomi Thomas, Thierry Flandre	0
2	Exploring Greater Flexibility for Chronic Toxicity Study Designs to Support Human Safety Assessment While Balancing 3Rs Considerations 2024 ·International Journal of Toxicology ·Helen Prior, Paul Baldrick, David O. Clarke, Elisa Passini, Fiona Sewell, (unknown)	3
3	Exploring the Definition of “Similar Toxicities”: Case Studies Illustrating Industry and Regulatory Interpretation of ICH S6(R1) for Long-Term Toxicity Studies in One or Two Species 2022 ·International Journal of Toxicology ·Helen Prior, David O. Clarke, D. I. Jones, (unknown), Melissa M. Schutten, Fiona Sewell	5
4	Strategies and Recommendations for Using a Data‐Driven and Risk‐Based Approach in the Selection of First‐in‐Human Starting Dose: An International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) Assessment 2020 ·Clinical Pharmacology & Therapeutics ·Michael W. Leach, David O. Clarke, Sherri Dudal, Chao Han, Chunze Li, Zheng Yang, Frank R. Brennan, Wendy J. Bailey, Yingxue Chen, Antoine Deslandes, (unknown), Kapil Mayawala, Mark Rogge, Marque D. Todd, Nagendra Chemuturi	17
5	An assessment of the central disposition of intranasally administered insulin lispro in the cerebrospinal fluid of healthy volunteers and beagle dogs 2016 ·Drug Delivery and Translational Research ·Stephen L. Lowe, Emanuele Sher, Graham N. Wishart, Kimberley Jackson, Eunice Yuen, Claire Brittain, (unknown), David O. Clarke, William Landschulz	8
6	The Use of Minipigs for Preclinical Safety Assessment by the Pharmaceutical Industry 2016 ·Toxicologic Pathology ·Curtis Colleton, David Brewster, Anne Chester, David O. Clarke, Peter Heining, Andrew Olaharski, Michael J. Graziano	28
7	Assessment of ixekizumab, an interleukin-17A monoclonal antibody, for potential effects on reproduction and development, including immune system function, in cynomolgus monkeys 2015 ·Reproductive Toxicology ·David O. Clarke, (unknown), (unknown), (unknown), Gary J. Chellman	17
8	A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorder 2013 ·Psychopharmacology ·Himanshu P. Upadhyaya, D. Desaiah, Kory Schuh, Frank P. Bymaster, Mary Jeanne Kallman, David O. Clarke, Todd M. Durell, Paula T. Trzepacz, David O. Calligaro, Eric S. Nisenbaum, Paul J. Emmerson, Leslie M. Schuh, Warren K. Bickel, Albert J. Allen	44
9	The effects of collagen synthesis inhibitory drugs on somitogenesis and myogenin expression in cultured chick and mouse embryos 2001 ·Tissue and Cell ·Ellen A.G. Chernoff, David O. Clarke, (unknown), (unknown), Rosamund C. Smith	3
10	The Selective Estrogen Receptor Modulator, Raloxifene: Reproductive Assessments Following Preimplantation Exposure in Mated Female Rats 11These studies were conducted in accordance with the Food and Drug Administration “Good Laboratory Practice Regulations for Nonclinical Laboratory Studies.” CRF Part 58, 1978. 1998 ·Reproductive Toxicology ·David O. Clarke, Kelly I. Griffey, (unknown), Paul C. Francis	9
11	Pharmacokinetics of 2-Methoxyethanol and 2-Methoxyacetic Acid in the Pregnant Mouse: A Physiologically Based Mathematical Model 1993 ·Toxicology and Applied Pharmacology ·David O. Clarke, Barbara A. Elswick, Frank Welsch, Rory B. Conolly	34
12	Pharmacokinetic Studies in Developmental Toxicology: Practical Considerations and Approaches 1993 ·Toxicology Methods ·David O. Clarke	11
13	2-Methoxyethanol metabolism in pregnant CD-1 mice and embryos 1992 ·Toxicology and Applied Pharmacology ·Charles A. Mebus, David O. Clarke, Donald B. Stedman, Frank Welsch	13
14	2-Methoxyacetic acid dosimetry-teratogenicity relationships in CD-1 mice exposed to 2-methoxyethanol 1992 ·Toxicology and Applied Pharmacology ·David O. Clarke, (unknown), Frank Welsch	30
15	A Critical Review of the Toxicology of Glutaraldehyde 1992 ·Critical Reviews in Toxicology ·Robert O. Beauchamp, (unknown), Timothy R. Fennell, David O. Clarke, Kevin T. Morgan, (unknown)	175
16	Characterization of urinary metabolites from [1,2,methoxy-13C]-2-methoxyethanol in mice using carbon-13 nuclear magnetic resonance spectroscopy 1992 ·Chemical Research in Toxicology ·Susan Sumner, (unknown), David O. Clarke, Frank Welsch, Timothy R. Fennell	14
17	Protection against 2-methoxyethanol-induced teratogenesis by serine enantiomers: Studies of potential alteration of 2-methoxyethanol pharmacokinetics 1991 ·Toxicology and Applied Pharmacology ·David O. Clarke, Charles A. Mebus, Frederick J. Miller, Frank Welsch	19
18	Adaptation of postimplantation embryos to culture: Membrane lipid synthesis and response to valproate 1991 ·Reproductive Toxicology ·Nigel A. Brown, David O. Clarke, Afshan McCarthy	14
19	Valproic Acid Teratogenesis and Embryonic Lipid Metabolism 1987 ·PubMed ·David O. Clarke, Nigel A. Brown	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact